SEC Form 4 · accession 0001477932-18-006021
Cure Pharmaceutical Holding Corp. · CURR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Period of report
Nov 8, 2017
Accepted (ET)
Dec 17, 2018 · 9:51 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001643301
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 7, 2018 | M | 297,288 | $0.886 | A | 3,495,932 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantF3,F2 | $7.00 | Nov 8, 2017 | P | 50,000 | A | Nov 8, 2017 | Nov 8, 2020 | Common Stock | 50,000 | 50,000 | D |
| WarrantF5,F6,F4 | $1.00 | May 15, 2018 | P | 148,644 | A | May 15, 2018 | May 15, 2021 | Common Stock | 148,644 | 198,644 | D |
Explanation of responses
- F1Conversion of Convertible Promissory Note.
- F2The conversion price is the lesser of $7.00 or the price per share of the latest closing of a debt or equity offering by the Issuer greater than $3,000,000.
- F3$250,000 is the principal amount paid for both a convertible note and the warrant on November 8, 2017.
- F4Exercise price per share equal to the lower of (a) $1.00 or (b) 125% of the price of a qualified offering, and to purchase up to a number of shares of common stock equal to 50% of the number of shares of common stock issuable upon conversion of such purchaser's note.
- F5The number of warrant shares are equal to fifty percent (50%) of the number of shares of common stock issued upon conversion of the note at the applicable conversion price under the note converted on 7/7/2018.
- F6$250,000 is the principal amount paid for both a convertible note and the warrant on May 15, 2018.